The expression of Siglec-14 on PMN, however, remains to be shown, since all available antibodies against Siglec-14 may cross-react with Siglec-5 due to the sequence identity between these paired Siglec receptors that balance immune responses to pathogens (60) and other models of breast tumor cells (61) than the ones used in our study. This evidence concerns the gene SIGLEC14 and breast neoplasm.